Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Advanced Search
  • Mar 2, 2021
    - Study of more than 10,000 people identifies a rare group with controlled HIV in the Democratic Republic of Congo, suggesting additional research could uncover links between natural virus suppression and future treatments
    - Discovery is a result of Abbott's continued virus hunting efforts, which also uncovered a new strain of HIV in 2019
    - Abbott's decades of work in global viral surveillance has advanced the understanding of HIV and allowed the company to quickly respond to the COVID-19 pandemic with its diagnostic tests
  • Feb 1, 2021
    - Support for the Easterseals Black Child Fund Will Advance Early Identification and Interventions Among Black Children to Reduce Health Disparities Often Experienced in Early Childhood
  • Jan 27, 2021
    - Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales
    - Sales growth of 28.7 percent; organic sales growth of 28.4 percent
    - GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent
    - Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020
    - R&D pipeline continues to be highly productive, delivering ground-breaking innovations and a steady cadence of important new products across all business areas
    - Issues 2021 EPS growth forecast of more than 35 percent
  • Jan 26, 2021
    - Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic
    - Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers
    - Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional's supervision
    - Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology
    - Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads
    - Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends
    - Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide
Show 5102550100 per page
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?